dc.creator | Papadopoulou A., Zafiriou E., Koukoulis G.K., Roussaki-Schulze A.V. | en |
dc.date.accessioned | 2023-01-31T09:42:44Z | |
dc.date.available | 2023-01-31T09:42:44Z | |
dc.date.issued | 2020 | |
dc.identifier | 10.1111/jdv.16243 | |
dc.identifier.issn | 09269959 | |
dc.identifier.uri | http://hdl.handle.net/11615/77633 | |
dc.description.abstract | [No abstract available] | en |
dc.language.iso | en | en |
dc.source | Journal of the European Academy of Dermatology and Venereology | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85079859962&doi=10.1111%2fjdv.16243&partnerID=40&md5=5fdc0983290050bc8c701817106a8c1c | |
dc.subject | hydroxymethylglutaryl coenzyme A reductase inhibitor | en |
dc.subject | loop diuretic agent | en |
dc.subject | coenzyme A | en |
dc.subject | drug | en |
dc.subject | oxidoreductase | en |
dc.subject | aged | en |
dc.subject | antiinflammatory activity | en |
dc.subject | bullous pemphigoid | en |
dc.subject | case control study | en |
dc.subject | controlled study | en |
dc.subject | drug effect | en |
dc.subject | enzyme linked immunosorbent assay | en |
dc.subject | female | en |
dc.subject | human | en |
dc.subject | ICD-10 | en |
dc.subject | Letter | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | predictive value | en |
dc.subject | priority journal | en |
dc.subject | retrospective study | en |
dc.subject | skin protection | en |
dc.subject | bullous pemphigoid | en |
dc.subject | Coenzyme A | en |
dc.subject | Humans | en |
dc.subject | Oxidoreductases | en |
dc.subject | Pemphigoid, Bullous | en |
dc.subject | Pharmaceutical Preparations | en |
dc.subject | Blackwell Publishing Ltd | en |
dc.title | Drugs associated with bullous pemphigoid: role of ΗΜG-COa reductase inhibitors | en |
dc.type | other | en |